SCHEMBL10175703

SCHEMBL10175703

CC(Oc1cccc(Cl)c1)C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.79

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.78
L3MBTL1 Q9Y468 1/20 0.78
OGG1 O15527 1/20 0.68
ALDH1A1 P00352 3/20 0.59
KDM4E B2RXH2 1/20 0.59
GAA P10253 1/20 0.59
MEN1 O00255 2/20 0.57
RXFP1 Q9HBX9 1/20 0.57
TSHR P16473 1/20 0.56
POLB P06746 1/20 0.56
PKM P14618 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
ADORA2A P29274 1/20 0.55
ADORA1 P30542 1/20 0.55
ATM Q13315 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2610075 0.88 KMT2A (0.72) KMT2AL3MBTL1MEN1RXFP1TSHR
SCHEMBL2610073 0.88 KMT2A (0.72) KMT2AL3MBTL1MEN1RXFP1TSHR
SCHEMBL10175988 0.88 KMT2A (0.72) KMT2AL3MBTL1MEN1RXFP1TSHR
SCHEMBL10175701 0.86 KMT2A (0.62) KMT2AL3MBTL1ALDH1A1KDM4EGAA
SCHEMBL28577960 0.84 KMT2A (0.62) KMT2AL3MBTL1ALDH1A1MEN1RXFP1
SCHEMBL29768501 0.84 KMT2A (0.62) KMT2AL3MBTL1ALDH1A1MEN1RXFP1
SCHEMBL29768421 0.84 KMT2A (0.62) KMT2AL3MBTL1ALDH1A1MEN1RXFP1
SCHEMBL29768415 0.84 KMT2A (0.62) KMT2AL3MBTL1ALDH1A1MEN1RXFP1
SCHEMBL28584658 0.84 KMT2A (0.62) KMT2AL3MBTL1ALDH1A1MEN1RXFP1
SCHEMBL10064815 0.84 KMT2A (0.64) KMT2AL3MBTL1OGG1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150099781-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-09 US disclosed
US-8969342-B2 Compounds and methods for treating mammalian gastrointestinal microbial infections BRANDEIS UNIVERSITY (US) 2015-03-03 US disclosed
US-20120101096-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections University of Georgia Foundation, Inc. (US) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101096-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections IMPDH1, IMPDH2, IMPA1 KMT2A 3016/4885L3MBTL1 2101/4885OGG1 350/4885
US-20150099781-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections IMPDH1, IMPDH2, IMPA1 KMT2A 3016/4885L3MBTL1 2101/4885OGG1 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.